Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
International Journal of Clinical Oncology Aug 10, 2017
Matsubara N, et al. – The efficacy and safety of radium–223 were inspected in Japanese patients with symptomatic castration–resistant prostate cancer (CRPC) and bone metastases. For this group of patients, this study outlined the efficacy and well tolerance of Radium–223. It was reported that results were comparable with the Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
